Former Chairman and CEO “Pete” Petit Highlights Flaws in Revenue Recognition Allegations

MARIETTA, Ga.–(BUSINESS WIRE)–Former Chairman and CEO Pete Petit of Mimedx Group, Inc. (OTC PINK:
MDXG) (‘MiMedx”) issued the following statement to fellow shareholders:

All the revenue recognition allegations against MiMedx purposefully
ignore the stark reality that the Company collected basically all of its
booked revenue over the years. In addition, the Company bought over $130
million of its stock back without incurring debt or affecting revenue
and profit growth.

Channel stuffing results in reduced cash collections and the aging of
accounts receivable. MiMedx suffered neither of these problems for the
wrong reasons for any extended period of time. Their accounts receivable
did age in 2015 right after Petit informed Avkare that they were going
to cancel their contract because the Company had received their own
federal supply contract. Avkare became upset and slowed down their
payments to MiMedx. That situation corrected itself when executive
management called Avkare out, and MiMedx accounts receivable came down
into the 70 day and then 60 day range.

So, the illegal short-sellers and the Company have BOTH ignored the
obvious indication that management did an effective job of collecting
revenue they reported in their quarterly financial statements. However,
the MOST IMPORTANT concept that is being ignored is the fact that Petit,
Taylor, Senken and Cranston met at the end of each quarter and reviewed
and generally increased the reserves for “Returns and Allowances” which
reduced quarterly revenues and the “Bad Debt Reserves” which reduced
quarterly profits.

Thus, this is the way that management assured that all the potential
small perturbations in revenue recognition were adequately dealt for
dealers and other customers as thousands of purchase orders were
processed each quarter. The Company’s reserves certainly must have been
adequate because of its collection record.

It is most frustrating that this current Board has accused former
management of financial malfeasance. The Board has had the ability to
assess these financial parameters, which means they should not have made
unfounded accusations. Obviously, they have crafted a story that
justifies the “for cause” terminations of management and their takeover
of the Company.

It is very disappointing to see the extent of misinformation and actual
lies contained in the MiMedx press release and 8K dated May 23rd and
their press release of June 10th. Executive management has never been
given a meaningful opportunity to review ANY of these specific
allegations or been able to respond until now, except for the
recommended revenue recognition changes for 2012-2016, which management
totally disagreed with in June of 2018.

The nine bullet points of allegations in the Company’s communications
are twisted and knowingly incorrect conclusions from thousands of emails.

It is Mr. Petit’s contention that he and his staff conducted MiMedx
business with honesty and integrity without knowingly violating
regulations, laws or GAAP accounting.

This is the first time since his departure that Mr. Petit has actually
seen these allegations. The Company provided him with a few hundred
emails for his review in 2018. He had questions about two or three of
them, but was ultimately satisfied that nothing was amiss. Of course, a
former prosecutor will twist communications to match their desired goals
at times.

Some specific comments on the Company’s false allegations are:

  • The distributor who obtained a consulting contract always purchased
    product over the years in large quantities toward the end of a
    quarter. The consulting contract was for very valid intelligence
    information on our competition.
  • The sale to a distributor that was acquired was two quarters prior to
    their purchase. They became a subsidiary of the Company so no payment
    had to be made.
  • The Company never shipped products to Mr. Petit’s knowledge without a
    valid purchase order and that were “not needed” due to the strong
    demand for our products.
  • Mr. Petit is confident that specific allegations can be refuted, once
    they are openly presented.

Please refer to the proxy contest website,, for new
information that will be posted today and tomorrow. Please remember the
importance of voting for Proposals #2 and #3 on the white proxy card in
order to ensure shareholder rights are respected and not modified by an
entrenched Board. This is important in order to ensure a 2019
shareholder meeting in the short term so that additional new Board
members can be elected.


Parker H. Petit (“Mr. Petit”), David J. Furstenberg, and Shawn P. George
(collectively, the “Nominees” or the “Participants”) have filed a
definitive proxy statement and supplements to the definitive proxy
statement with the Securities and Exchange Commission (the “SEC”), along
with an accompanying WHITE proxy card to be used in connection with the
Participants’ solicitation of proxies from the shareholders of MiMedx
Group, Inc. (the “Company”) for use at the Company’s 2018 annual meeting
of shareholders. All shareholders of the Company are advised to read the
foregoing proxy materials because they contain important information,
including additional information related to the Participants. The
definitive proxy statement and supplements and an accompanying proxy
card will be furnished to some or all of the Company’s shareholders and
are, along with other relevant documents, available at no charge on the
SEC’s website at
and at

Information about the Participants and a description of their direct or
indirect interests by security holdings are contained in the definitive
proxy statement on Schedule 14A filed by Mr. Petit with the SEC on May
28, 2019. This document can be obtained free of charge from the sources
indicated above.


Proxy Solicitor:
John Glenn Grau
(877) 972-0090
Banks and Brokers Call Collect: (203) 972-9300